Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potent antiviral activity of simnotrelvir against key epidemic SARS-CoV-2 variants with a high resistance barrier

10 Mar 2025

Abstract excerpt

ABSTRACT Simnotrelvir is an oral small-molecule antiviral agent targeting the 3C-like protease (3CL pro ) of SARS-CoV-2, proven effective against the Delta variant with favorable pharmacokinetics and safety in preclinical study. In this study, we further evaluated the antiviral efficacy of simnotrelvir against a range of emerging Omicron variants, including BA.1, BA.4, BA.5, CH.1.1, XBB.1.5, XBB.1.16, EG.5, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to SARS-CoV-2 detection and testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40062859
DOI: 10.1128/aac.01556-24

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potent antiviral activity of simnotrelvir against key epidemic SARS-CoV-2 variants with a high resistance barrierPMID 40062859Read ↗

A comprehensive study of SARS-CoV-2 main protease (M <sup>pro</sup> ) inhibitor-resistant mutants selected in a VSV-based systemSemantic proximity Read ↗

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitorsSemantic proximity Read ↗

Multiple pathways for SARS-CoV-2 resistance to nirmatrelvirSemantic proximity Read ↗

In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvirSemantic proximity Read ↗

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitorsSemantic proximity Read ↗

Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.Semantic proximity Read ↗

SARS-CoV-2 3CLpro mutations T21I and E166A confer differential resistance to simnotrelvir, bofutrelvir, and ensitrelvir.Semantic proximity Read ↗

A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system.Semantic proximity Read ↗

Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to NirmatrelvirSemantic proximity Read ↗

Cross-resistance patterns in SARS-CoV-2 against 3CL protease inhibitors.Semantic proximity Read ↗

A SARS-CoV-2 Mpro mutation conferring ensitrelvir resistance paradoxically increases nirmatrelvir susceptibilitySemantic proximity Read ↗

SARS-CoV-2 Resistance to Small Molecule InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.